Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?

23 Aug 2018

Abstract excerpt

Bladder cancer therapy relies on aggressive treatments highlighting the need for new, targeted therapies with reduced side effects. SWI/SNF complexes are mutated in ~20% across human cancers and dependency of SWI/SNF-deficient tumors on EZH2 has been uncovered recently. To systematically dissect the frequency of genetic alterations in SWI/SNF complexes potentially contributing to their inactivation, mutations and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Neuroendocrine Tumor Research Advances
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30138427
DOI: 10.1371/journal.pone.0202965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?PMID 30138427Read ↗

Therapeutic significance of ARID1A mutation in bladder cancer.Semantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial CarcinomaSemantic proximity Read ↗

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibitionSemantic proximity Read ↗

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsSemantic proximity Read ↗

ARID1A loss in cancer: Towards a mechanistic understanding.Semantic proximity Read ↗

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder TumorsSemantic proximity Read ↗

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomasSemantic proximity Read ↗

Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant SubtypesSemantic proximity Read ↗

The spectrum of SWI/SNF mutations, ubiquitous in human cancers.Semantic proximity Read ↗

ARID1A: gene, protein, and function in endometrial cancer.Semantic proximity Read ↗

EZH2 in Bladder Cancer, a Promising Therapeutic TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.